A double-blind, randomized phase II study of S-1 plus resminostat versus S-1 plus placebo in patients with platinum-gemcitabine combination refractory biliary tract cancer (BTC).

Trial Profile

A double-blind, randomized phase II study of S-1 plus resminostat versus S-1 plus placebo in patients with platinum-gemcitabine combination refractory biliary tract cancer (BTC).

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Apr 2018

At a glance

  • Drugs Resminostat (Primary) ; Gimeracil/oteracil/tegafur
  • Indications Biliary cancer; Cholangiocarcinoma; Gallbladder cancer
  • Focus Therapeutic Use
  • Sponsors Yakult Honsha
  • Most Recent Events

    • 19 Apr 2018 Final results are expected to be available by mid-2020, according to a 4SC media release.
    • 09 Apr 2018 Status changed from not yet recruiting to recruiting.
    • 21 Mar 2018 According to a 4SC media release, this trial is expected to initiate in in H1 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top